Home' Australian Pharmacist : Australian Pharmacist December 2012 Contents 976 Australian Pharmacist December 2012 I ©Pharmaceutical Society of Australia Ltd.
Continuing Professional Development
Submit your answers online before
1 February 2013 at www.psa.org.au
and receive automatic feedback, or
PSA CPD answers
Pharmaceutical Society of Australia,
Level 1, 381 Royal Parade,
PARKVILLE VIC 3052
Fax: (03) 9389 4044
NZCP CPD answers,
PO Box 11 640,
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA's
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4 out
of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
If not submitting online, write the correct answers
in the spaces provided on the answer panel on
the back of the address sheet, fill in your name,
member number and address details, then either
mail or fax the answer page to the relevant
address and fax number for marking.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
1. Which ONE of the following insulins
has been proven to increase the
incidence of some cancer types in
a) Insulin glargine.
b) Normal human insulin.
c) Insulin AspB10.
d) Lispro insulin.
2. Which ONE of the following was
NOT a characteristic of the four
2009 studies that investigated
the relationship between insulin
glargine and cancer?
a) All were retrospective observational
b) Each study found a consistently
elevated risk of cancer with the use of
c) The duration of these studies may have
been too short for insulin glargine to
increase the occurrence of cancer.
d) Some of the studies involved poorly
matched cohorts of participants.
3. An increased risk of which ONE of
the following types of cancer has
MOST frequently been associated
with the use of insulin glargine?
a) Breast cancer.
b) Skin cancer.
c) Colon cancer.
d) Lung cancer.
4. Which ONE of the following
statements regarding the evidence
between insulin glargine increasing
the risk of cancer is MOST
a) The use of insulin glargine should
be avoided if possible as it has been
shown conclusively to increase cancer
b) Insulin glargine has been shown
conclusively to not increase the risk of
all cancer types.
c) A number of prospective randomised
controlled trials have investigated the
association between insulin glargine
use and cancer.
d) There is insufficient evidence for
insulin glargine increasing the risk of
cancer to be a consideration in insulin
1. Stafford AC, Tenni PC, Peterson GM, et al. Drug-related
problems identified in medication reviews by Australian
pharmacists. Pharm World Sci 2009;31:216--23.
2. Nathan D, Buse J, Davidson M, et al. Medical management
of hyperglycaemia in type 2 diabetes mellitus: a consensus
algorithm for the initiation and adjustment of therapy.
3. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like
growth factor-I (IGF-I), IGF binding proteins, their biologic
interactions, and colorectal cancer. J Natl Cancer Inst
4. Dawson LK, Hamilton LA. Risk of cancer in patients receiving
insulin glargine. Am J Health Syst Pharm 2010;67:2025--31.
5. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of
receptor binding and metabolic and mitogenic potencies of
insulin analogs designed for clinical use. Diabetes 2000;49:999--
6. Smith U, Gale EA. Does diabetes therapy influence the risk of
cancer? Diabetologia 2009;52:1699--708.
7. Colhoun HM. Use of insulin glargine and cancer incidence in
Scotland: a study from the Scottish Diabetes Research Network
Epidemiology Group. Diabetologia 2009;52:1755--65.
8. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering
therapies on cancer risk in type 2 diabetes. Diabetologia
9. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies
in patients with diabetes treated with human insulin or insulin
analogues: a cohort study. Diabetologia 2009;52:1732--44.
10. Jonasson JM, Ljung R, Talback M, et al. Insulin glargine use and
short-term incidence of malignancies -- a population-based
follow-up study in Sweden. Diabetologia 2009;52:1745--54.
11. Suissa S, Azoulay L, Dell'Aniello S, et al. Long-term effects of
insulin glargine on the risk of breast cancer. Diabetologia
12. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer
in patients on insulin glargine and other insulin analogues
in comparison with those on human insulin: results from
a large population-based follow-up study. Diabetologia
13. Boyle P. Northern European database study of insulin and
cancer risk. In: American Diabetes Association 72nd Scientific
Sessions; 2012 June 8--12. Philadelphia, United States; 2012.
14. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and
cardiovascular and other outcomes in dysglycemia. N Engl J
15. Habel L. Results from Kaiser-Permanente Collaboration. In:
American Diabetes Association 72nd Scientific Sessions; 2012
Jun 8--12. Philadelphia, United States; 2012.
16. Sturmer T. Results from claims data and a focus on incident
user analysis. In: American Diabetes Association 72nd Scientific
Sessions; 2012 Jun 8--12. Philadelphia, United States; 2012.
17. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia
with macrovascular and microvascular complications of type 2
diabetes (UKPDS 35): prospective observational study. Br Med
18. ADS position statement on insulin glargine (Lantus®) and a
possible link with cancer.2009 December 15, updated 2012
October 17. Sydney: Australian Diabetes Society. Available
pdf [cited 2012 November 12]
Links Archive Australian Pharmacist January 2013 Australian Pharmacist November 2012 Navigation Previous Page Next Page